Last reviewed · How we verify
NCT04925804
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)
trial in Hypophosphatasia in 16 participants. Completed in 2 December 2021.
2 December 2021
Quick facts
| Lead sponsor | CENTOGENE GmbH Rostock |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 2 June 2021 |
| Primary completion | 2 December 2021 |
| Estimated completion | 2 December 2021 |
| Sites | 1 location across Germany |
Conditions studied
- Hypophosphatasia — all drugs for Hypophosphatasia →
Sponsor
CENTOGENE GmbH Rostock
Who can join
Eligibility, any sex, with Hypophosphatasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Observational study to perform Whole Genome Sequencing in participants clinically suspected for HPP and negative for known pathogenic ALPL variants
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Whole genome sequencing in adults with clinical hallmarks of hypophosphatasia negative for ALPL variants.
Seefried L, Petryk A, Del Angel G, Reder F, et al · · 2024 · cited 3× · PMID 39276275 · DOI 10.1007/s11033-024-09906-7
Verify or expand the search:
- PubMed search for NCT04925804
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypophosphatasia
Currently open trials in the same condition.
- NCT07390240 — The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia · recruiting
- NCT06079359 — Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP · Phase 3 · active not recruiting
- NCT06079372 — Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa · Phase 3 · active not recruiting
- NCT06079281 — Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Trea · Phase 3 · active not recruiting
- NCT05234567 — A Prospective Sub-Study of the Global Hypophosphatasia Registry · recruiting
Other CENTOGENE GmbH Rostock trials
Trials by the same sponsor.
- NCT06040008 — Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals · completed
- NCT05075187 — Epidemiological Study in FRONtoTemporal Dementia · completed
- NCT04548921 — Biomarker for Friedreich's Ataxia (BioFridA) · unknown
- NCT03866590 — Pyruvate Kinase Deficiency Epidemiological Study (PIECE) · completed
- NCT04091113 — Hereditary Angioedema Kininogen Assay · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04925804 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CENTOGENE GmbH Rostock
- Last refreshed: 29 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04925804.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing